Caplin Point gets Colombia approval for Softgel Capsules

Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE: CAPLIPOINT) has received Colombia's INVIMA approval for its Softgel Capsules division at Puducherry. The site inspection of Unit-1 was completed on May 3rd and found compliant as per INVlMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).

Commenting on the approval, Mr.C.C.Paarthipan, Chairman, Caplin Point Laboratories Limited said "Expansion into larger markets of Latin America such as Colombia, is an important aspect of our future growth, and this approval, especially in the niche Softgel Capsules range will contribute well to the same."

The Unit currently caters to Emerging Markets of Latin America and Africa with a variety of dosage forms such as Tablets, Capsules, Softgel Capsules, Suppositories, Liquid Orals, Topicals and Injectables.

Shares of Caplin Point Laboratories Limited was last trading in BSE at Rs. 1311.00 as compared to the previous close of Rs. 1298.80. The total number of shares traded during the day was 19292 in over 2163 trades.

The stock hit an intraday high of Rs. 1330.00 and intraday low of 1277.85. The net turnover during the day was Rs. 25132429.00.

Source : Equity Bulls

Keywords

CaplinPointLaboratories INE475E01026 Colombia INVIMAApproval SoftgelCapsulesDivision Puducherry